Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Thrombocytopenia 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 35Mycophenolic Acid 33Whole-Body Irradiation 32Busulfan 24Tacrolimus 22fludarabine 21Peripheral Blood Stem Cell Transplantation 20Cyclosporine 20Melphalan 17Antilymphocyte Serum 13Methotrexate 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Cytarabine 11Cord Blood Stem Cell Transplantation 11Thiotepa 9thymoglobulin 8eltrombopag 8Lenalidomide 7Etoposide 7Epoetin Alfa 7Dalteparin 7romiplostim 6Darbepoetin alfa 6Alemtuzumab 6merphos 5apixaban 5Sirolimus 5Radiotherapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × oprelvekin × Classical hematology × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡